A SMARCB1-deficient vulvar neoplasm with prominent myxoid stroma: report of a case showing ERG and FLI1 expression.

Shogo Tajima, Yusuke Takahasi, Michi Hikoaki, Rei Goto

Open access · greenAbstract readCase Reports

In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.2field-weighted citation impact, top 45% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

Pathologic and genomic characteristics of myoepithelioma-like tumor of the vulvar region: three case reports.Diagnostic pathology · 2025
Article
A case of retroperitoneal tumor displaying epithelial differentiation, prominent myxoid stroma and loss of INI1/SMARCB1.Pathologica · 2021
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Shogo TajimaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.

Yusuke TakahasiDepartment of Surgery, Fujieda Municipal General Hospital Shizuoka, Japan.

Michi HikoakiDepartment of General Education Center, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.

Rei GotoDepartment of Radiology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.

Fujieda Municipal General Hospital · JPJapan Graduate School of Education University · JPThe University of Tokyo · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the vulvar region, epithelioid sarcoma (ES) is the most frequent SMARCB1-deficient neoplasm, followed by myoepithelial carcinoma (MC). Previous studies have demonstrated that some SMARCB1-deficient vulvar neoplasms cannot be classified as either ES or MC. Herein, we report of a 42-year-old woman with a SMARCB1-deficient neoplasm with prominent myxoid stroma in the vulva. It contained both epithelioid and spindled tumor cells, both of which showed vimentin and EMA expression. Although other markers useful for the differential diagnosis among SMARCB1-deficient tumors were negative, this tumor displayed characteristic expression of ERG and FLI1. As there are no reliable data regarding expression of ERG and FLI1 in MC, which are demonstrated to be often expressed in ES, further classification of cases such as the one reported here requires reliable data regarding their expression status in MC.

Indexed as

AdultBiomarkers, TumorChromosomal Proteins, Non-HistoneDNA-Binding ProteinsDown-RegulationFemaleHumansImmunohistochemistryMagnetic Resonance ImagingProto-Oncogene Protein c-fli-1SarcomaSMARCB1 ProteinStromal CellsTrans-ActivatorsTranscriptional Regulator ERGTranscription FactorsBiomarkers, TumorChromosomal Proteins, Non-HistoneDNA-Binding ProteinsERG protein, humanFLI1 protein, humanProto-Oncogene Protein c-fli-1SMARCB1 ProteinSMARCB1 protein, humanTrans-ActivatorsTranscriptional Regulator ERGTranscription FactorsERGFLI1myxoid stromaneoplasmSMARCB1/INI1vulva

Identifiers

PMID26261664

PMCPMC4525998

OpenAlexW1484084052

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.